Combination therapy reduced HER2-positive breast cancers
Friday, December 10, 2010 - 10:20
in Health & Medicine
A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to new data.